ライフサイエンスコーパス: tumor patient

1 xon 5 of wt1 in a sporadic unilateral Wilms' tumor patient.

2 mental to the long-term health of the kidney tumor patient.

3 but cannot prove causality in the individual tumor patient.

4 e way for new immune therapy trials in brain tumor patients.

5 n a challenging task in the therapy of brain tumor patients.

6 y into the tumor resection cavities of brain tumor patients.

7 r potential power in the evaluation of brain tumor patients.

8 tant AR (mtAR T877A), found in many prostate tumor patients.

9 t for clinical validation in KRAS-stratified tumor patients.

10 bs may improve the current therapy for brain tumor patients.

11 tested, including Mer- specimens from brain tumor patients.

12 using data obtained during brain mapping in tumor patients.

13 ents found in the blood stream of metastatic tumor patients.

14 ly supports the clinical management of brain tumor patients.

15 ortant tool for response assessment in brain tumor patients.

16 DNA methylation across 1292 pediatric brain tumor patients.

17 age PDXs established from 65 pediatric solid tumor patients.

18 ategies for improving ICB efficacy for brain tumor patients.

19 d 67% (95% CI, 29.9 to 92.5) in the DKK1-low tumor patients.

20 tors of preoperative VFDs in pediatric brain tumor patients.

21 tilized to advance immunotherapies for solid tumor patients.

22 This meta-analysis included 4592 tumor patients.

23 charge outcome and shorter survival of brain tumor patients.

24 mapping and successfully applied it to brain tumor patients.

25 ated with cell proliferation and activity in tumor patients.

26 risk estimations for subpopulations of brain tumor patients.

27 strated utility in the current care of brain tumor patients.

28 rognostic biomarkers for clinical outcome in tumor patients.

29 clinical decision making in pediatric brain tumor patients.

30 associated with systemic toxicities in brain tumor patients.

31 ls is successfully applied in neuroendocrine tumor patients.

32 gnostic biomarker for OS and DFS in Klatskin tumor patients.

33 etwork-based view of these deficits in brain tumor patients.

34 rapeutic potential in GH-producing pituitary tumor patients.

35 intervention has rapidly improved for brain tumor patients.

36 no acid transport in the management of brain tumor patients.

37 development and determine survival in brain tumor patients.

38 it to be a germline genetic event in thyroid tumor patients.

39 observed in nontransplanted, immunized solid-tumor patients.

40 ngs in genomic DNA from normal tissues of GI tumor patients.

41 nced carcinoid and pancreatic neuroendocrine tumor patients.

42 imited efficacy in metastatic neuroendocrine tumor patients.

43 in the germ line of hyperparathyroidism-jaw tumor patients.

44 nd quality of life (QOL) in irradiated brain tumor patients.

45 ession contributes to the prognosis of Wilms tumor patients.

46 higher relapse and mortality rates in Wilms tumor patients.

47 rove the still dismal survival rate of Ewing tumor patients.

48 , and 15 of a 28-day cycle in advanced solid tumor patients.

49 r for predicting treatment response in brain tumor patients.

50 intravenous infusion of decitabine in solid tumor patients.

51 art of the multimodality management of brain tumor patients.

52 erate antigen-specific cytotoxicity in brain tumor patients.

53 in serum when compared with LH/FSH-secreting tumor patients (0.269 +/- 0.139/0.167 +/- 0.113 mM in se

54 rom recurrent tumors on T1-w MRI in 42 brain tumor patients, (2) different molecular sub-types of bre

55 In solid tumor patients admitted between 2009 and 2013, hospital

56 was 7.7 months in pancreatic neuroendocrine tumor patients and 10.2 months in carcinoid patients.

57 dmission between 1997 and 2013; 39,734 solid tumor patients and 6,652 patients with a hematological m

58 90% (95% CI, 55.5 to 99.7) in the DKK1-high tumor patients and 67% (95% CI, 29.9 to 92.5) in the DKK

59 rate was 81.1% in pancreatic neuroendocrine tumor patients and 83.4% in carcinoid patients.

60 d fully automated evaluation of MTV in brain tumor patients and demonstrates clinical value for autom

61 apamycin (mTOR) inhibition in advanced solid tumor patients and in murine xenograft models.

62 is a core symptom reported by primary brain tumor patients and often manifests after radiotherapy.

63 bjective responses were noted in three Wilms tumor patients and one each of medulloblastoma and hepat

64 for treating venous thromboembolism in brain tumor patients and that the risk of hemorrhage with anti

65 We report changes in diagnosis for all brain tumor patients and the following relative differences va

66 munotherapy in specific subsets of germ cell tumor patients and the risk factors for resistance media

67 of [1,2-(13)C]acetate was validated in brain tumor patients and was correlated with expression of ace

68 dependent of age in the lymphocytes of brain tumor patients and was present in lymphocytes from six o

69 is mainly affected by a complex interplay of tumor, patient, and treatment-related factors.

70 estimated with multivariable adjustment for tumor-, patient-, and facility-level characteristics.

71 ical indications for amino acid PET in brain tumor patients are differentiation of neoplasm from nonn

72 icate that a significant proportion of solid tumor patients are eligible for immuno-targeted combinat

73 Cognitive deficits in brain tumor patients are reflected in whole-brain network dist

74 and promising preclinical experiments, brain tumor patients are still met with limited treatment opti

75 from patients with FCD I epilepsy, and from tumor patients as control.

76 on at large is not as profoundly impaired in tumor patients as the correct polarization, the survival

77 Pathologically, tumor patient-associated PDK1 mutations, either attenuat

78 C was administered every 14 days to 48 solid-tumor patients at doses of 5 to 59 microg/m2/h without g

79 ethyl)-l-tyrosine ((18)F-FET) from 555 brain tumor patients at initial diagnosis or during follow-up

80 and risk of other infections in 14,211 solid tumor patients at MSK.

81 xpressed Ag that is successfully targeted in tumor patients by mAbs or tyrosine kinase inhibitors.

82 A pilot study indicated that sera from brain tumor patients can be distinguished from controls based

83 We also identified a bladder tumor patient carrying a germ-line mutation but with no

84 Analysis of human primary CRC tumor patient databases showed a positive correlation be

85 in immunodeficient mice to establish primary tumor patient-derived xenograft (ptPDX) models.

86 nduces a specific type of CIN in patient HNC tumors, patient-derived xenografts, and cell lines, whic

87 ese technologies for the analysis of primary tumors, patient-derived xenografts, and in vitro systems

88 gle-cell/nucleus RNA sequencing from patient tumors, patient-derived xenografts, primary in vitro cul

89 Tracing ANGPTL4 and its fragments in tumor patients detected full-length ANGPTL4 primarily in

90 Mutations in MLLT1 observed in Wilms tumor patients enhance phase separation and transcriptio

91 ports the clinical use of DWI for pancreatic tumor patients for early assessment of drug efficacy.

92 e antineoplastic effects observed by some ES tumor patients from IGF-1R targeted therapies, in contra

93 n cancer predisposition genes across 830 CNS tumor patients from the Pediatric Brain Tumor Atlas (PBT

94 ly resected tumors from forty five pituitary tumor patients [gonadotropic (LH/FSH-secreting) = 17; pr

95 r of B cells in the peripheral blood of some tumor patients has been associated with poor immunothera

96 Although most germ cell tumor patients have a high survival rate, patients who e

97 dent factor for overall survival in Klatskin tumor patients (hazard ratio: 2.777; 95% confidence inte

98 and patient function is practical for brain tumor patients in clinical trials and can provide inform

99 Presence of CH in solid tumor patients, including colon cancer, correlates with

100 The most common medical problems in brain tumor patients involve the management of seizures, perit

101 evation in incidence of Mer- status in brain tumor patients is highly significant (chi2 = 24; p < or

102 Antiepileptic treatment of brain tumor patients mainly depends on the individual physicia

103 with paired biopsy cohort in advanced solid tumor patients, Module 1B-1 triple negative breast cance

104 red by Response Evaluation Criteria in Solid Tumors, patients on the standard-dose arm could reregist

105 , whereas grossly normal kidney tissues from tumor patients or renal cell carcinomas were CXCR2 negat

106 The incidence of bleeding is low among solid tumor patients overall but exceeds 20% in some subgroups

107 s as a whole can predict survival in stage I tumor patients (P = 0.01).

108 ctivity in this heavily pretreated germ cell tumor patient population.

109 prospectively enrolled pediatric type brain tumor patients, preserving tumor cytology and histoarchi

110 complete transurethral resection of bladder tumor, patients received either sequential intravesical

111 Solid tumor patients receiving immune checkpoint inhibitors be

112 discrimination of plasma derived from brain tumor patients relative to those derived from patients w

113 ressor gene (SMAD4) downregulated in our GBC tumor patient samples.

114 rge unselected institutional cohort of solid tumors patients sequenced at Dana-Farber / Boston Childr

115 itors of MMPs, clinical trials of late-stage tumor patients show no indication that this approach wil

116 Sixty-five percent (11/17) of brain tumor patients showed higher EV-GFAP than the maximum ob

117 Ninety-four percent (16/17) of tumor patients showed higher EV-Tau than the maximum obs

118 Anatomic location and stage of the tumor, patient sociodemographic characteristics, prior m

119 n at times prove causality in the individual tumor patient [such as the detection of high-risk human

120 Brain tumor patients suffer from cognitive deficits, regardles

121 alone has been insufficient to extend brain tumor patient survival.

122 For incidental tumors, patient survival was negatively influenced by mu

123 immuno-methylomic profiling in pediatric CNS tumor patients that may ultimately inform approach to im

124 In the testing group (brain tumor patients), the sensitivity of the language mapping

125 in the urine of normal and low-grade bladder tumor patients, the urine of high-grade bladder cancer p

126 ls.SIGNIFICANCE STATEMENT By comparing brain tumor patients to healthy children, we establish that ch

127 patients treated with BCT for larger breast tumors, patients treated with preoperative chemotherapy

128 ilm-positive colon mucosa were prepared from tumor patients (tumor and paired normal tissues from sur

129 ratory motion management strategies in liver tumor patients undergoing stereotactic body radiotherapy

130 response rate (ORR) in pancreatic endocrine tumor patients was 16.7% (11 of 66 patients), and 68% (4

131 The 5 years DSS for localized tumor patients was 35% for NF-1 patients and 50% for spo

132 verall immune-related response rate in solid tumor patients was 7.5% (95% CI 2.6-19.9); response was

133 A technique described in brain tumor patients was adapted to incorporate a correction f

134 er- status in normal brain tissue from brain tumor patients was age-dependent, increasing from 21% in

135 quency of liver metastases in neuroendocrine tumor patients, we aimed to determine whether hepatic in

136 abnormal microvasculature in malignant brain tumor patients, we have undertaken a cell-specific trans

137 f any abnormal hemodynamic profile for brain tumor patients, we propose our findings to be a close ap

138 Further PET/CT scans of tumor patients were acquired 1 h after injection of eith

139 Twenty brain tumor patients were examined by standard and diffusion M

140 Respiratory motion images of 23 liver tumor patients were obtained by 4DCT scan under abdomina

141 ectomy, and 4.0% (458/2736) had unresectable tumors.Patients were less likely to undergo surgery if t

142 ose escalation of TPT above the MTD in solid-tumor patients, whereas concurrent therapy with G-CSF an

143 ances in network topology are found in brain tumor patients, which relate to their cognitive problems

144 There is increasing evidence that brain tumor patients who have not had a seizure do not benefit

145 Results indicated that left tumor patients who presented with a lesion at or near so

146 Methods: We retrospectively analyzed brain tumor patients who underwent (18)F-FET PET/MRI between 2

147 in patients who had duodenal neuroendocrine tumors, patients who had GEP-NETs with no regional lymph

148 ulation of patients with superficial bladder tumors, patients who have p53 nuclear overexpression in

149 was present in lymphocytes from six of nine tumor patients whose normal brain specimen was Mer-.

150 Klatskin tumor patients with a history of tumor recurrence had si

151 Solid-tumor patients with a Karnofsky performance status great

152 Primary tumor patients with a subsequent brain relapse showed al

153 are feasible as PET imaging probes in brain tumor patients with activation of the kynurenine pathway

154 mples were taken during the ERC procedure in tumor patients with biliary obstruction.

155 of viral infection, especially in malignant tumor patients with common herpesvirus infection.

156 mmend palliative chemotherapy only for solid tumor patients with good performance status.

157 riate survival analysis showed that Klatskin tumor patients with high MACC1 had a significantly short

158 Methods: PRRT-naive adult neuroendocrine tumor patients with liver-dominant metastases were enrol

159 Outcome in tumor patients with malignant bile obstruction is associ

160 expression is elevated in high-grade primary tumor patients with papillary serous tumors of the ovary

161 al in a distinct subgroup of high-risk brain tumor patients with poor survival prognosis.

162 As tumor patients with probable CVD are treated with CAIX i

163 se levels as a method, for identifying brain tumor patients with the best likelihood of response to B

164 nse) viable tumors were designated as viable tumor; patients with solely LR-3 or LR-TR equivocal tumo

165 0.19-0.85) and PIK3CA/AKT1/PTEN-non-altered tumors (patients with confirmed next-generation sequenci

166 patients, female patients (for sex-specific tumors), patients with private health insurance, and pat

167 y in patients with advanced/metastatic solid tumors, patients with anaplastic thyroid carcinoma were

168 Compared with patients with PPARG-negative tumors, patients with PPARG-positive tumors had signific

169 In tumor patients without preoperative neurological deficit

170 Seizures are frequent complications in brain tumor patients, yet the underlying neuronal mechanisms r